Data from the Company’s Phase 2 Trial evaluating NE3107 in Parkinson’s Disease will be presented orally during the symposium Advances in PD and LDB Diagnosis and Drug Development (ID#124). A poster presentation on the pharmacokinetic profile of NE3107 will also be given. Both the oral presentation and poster will be available virtually throughout the event.
BioVie Announces Data from Phase 2 Parkin... - Cure Parkinson's
BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Dry Mouth, Gum Disease, Chapped Lips, Dry Eyes, Dry Skin, Eye Floaters And Some Possible Help From A Single Spray!
With winter just around the corner, this information may be most useful and timely! With winter...
Dopamine Dysregulation Syndrome
Definition here;
https://en.m.wikipedia.org/wiki/Dopamine_dysregulation_syndrome
How can docs be...
In Pursuit Of Restful Sleep And Help For Nocturia
One topic that seems to come up regularly on this forum is the issue of poor sleep or insomnia and...
If we accept that PD is basically a metabolic dysfunction...then electrolytes
The metabolic dysfunction theory as I understand it, states that the energy production factories...
Adding Sinemet to Mucuna
We're trying to go in the opposite direction of many here by adding Sinemet to Mucuna and are...
Carnivore Diet - Can't solidly recommend it
Optimising LD timings
Dr. Greger's view on NAD supplementation
CDP choline and dyskinesia 
